NEWS

For our visitors who seek the latest industry news and updates to keep abreast with the goings-on of the business on a global scale, Pharmaceutical Industry portal grants a dynamic and diverse feed of news items.

news

Cytovance® Biologics, Inc., announced that they have entered into a definitive agreement by which Hepalink USA Inc. will acquire Cytovance® Biologics Inc., a leading biopharmaceutical contract development manufacturing company. The addition of Cytovance Biologics to Hepalink USA Inc. and its parent company Shenzhen Hepalink Pharmaceutical Co., Ltd., adds a leading…

news

The U.S. Patent and Trademark Office on Monday rejected an attempt by prominent hedge fund manager Kyle Bass to challenge two patents on Acorda Therapeutics' flagship multiple sclerosis drug Ampyra. The decision to deny reviewing the patents comes as the pharmaceutical industry has raised concerns about hedge funds challenging the…

news

Medivation, Inc. and BioMarin Pharmaceutical Inc. said they have entered into an asset purchase agreement for Medivation to acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase or PARP inhibitor. It is currently in a Phase 3 study for the…

news

HBM Healthcare Investments AG : Raptor Pharmaceuticals Corp acquires rights to Quinsair. Raptor will pay $68.4 million upfront (of which up to $34.2 million in shares) as well as contingent milestone payments of up to $350 million plus single-digit royalties on global net sales. HBM Healthcare Investments will receive approximately…

news

Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.…

news

Novartis has agreed to buy all remaining rights to Ofatumumab from Britain's GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker's stable of multiple sclerosis (MS) treatments. Basel-based Novartis had previously acquired the rights to Ofatumumab for oncology indications, but it is currently being developed for relapsing remitting multiple…

news

Aurobindo Pharma today said it has received approval from the US health regulator to market generic version of Prilosec delayed-release capsules, used to treat ulcer, in the American market. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Omeprazole delayed-release capsules…

news

Glenmark Pharmaceuticals today said it has received final approval from the US health regulator to sell oral contraceptive -- drospirenone and ethinyl estradiol tablets -- in the US market. " Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone…

news

Corbus Pharmaceuticals Holdings Inc says investigational drug Resunab granted fast track status by FDA for the treatment of systemic sclerosis. Corbus Pharmaceuticals says scheduled to begin enrollment and dosing in its phase 2 study of Resunab this quarter.   reuters.com

news

Hunan China Sun Pharmaceutical Machinery Co Ltd Says plans to set up industry base in Foshan city with investment at 5 billion yuan ($781.74 million).   reuters.com